|
1
|
Jones GS and Baldwin DR: Recent advances
in the management of lung cancer. Clin Med (Lond). 18 Suppl
2:S41–S46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waqar SN and Morgensztern D: Treatment
advances in small cell lung cancer (SCLC). Pharmacol Ther.
180:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsvetkova E and Goss GD: Drug resistance
and its significance for treatment decisions in non-small cell lung
cancer. Curr Oncol. 19 Suppl 1:S45–S51. 2012.PubMed/NCBI
|
|
6
|
Barr MP, Gray SG, Hoffmann AC, Hilger RA,
Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and
O'Byrne KJ: Generation and characterisation of cisplatin-resistant
non-small cell lung cancer cell lines displaying a stem-like
signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rudolph C, Melau C, Nielsen JE, Jensen
Vile K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ and
Jørgensen A: Involvement of the DNA mismatch repair system in
cisplatin sensitivity of testicular germ cell tumours. Cell Oncol
(Dordr). 40:341–355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY,
Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating
microRNA signatures for breast cancer detection. Clin Cancer Res.
19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Natalie G, Walker RC, Hee KC, Winter S and
Hunter KW: Inherited variation in miR-290 expression suppresses
breast cancer progression by targeting the metastasis
susceptibility gene Arid4b. Cancer Res. 73:2671–2681. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guarnieri DJ and Dileone RJ: MicroRNAs: A
new class of gene regulators. Ann Med. 40:197–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wahid F, Shehzad AT, Khan T and Kim YY:
MicroRNAs: Synthesis, mechanism, function, and recent clinical
trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoelscher SC, Doppler SA, Dreßen M, Lahm
H, Lange R and Krane M: MicroRNAs: Pleiotropic players in
congenital heart disease and regeneration. J Thorac Dis. 9 Suppl
1:S64–S81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kastl L, Brown I and Schofield AC:
miRNA-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dongoran RA and Wu TY: Abstract 5269:
Cryptotanshinone activate Nrf2 expression through microRNA
regulations. Cancer Res. 77 Suppl 13:52692017. View Article : Google Scholar
|
|
16
|
Singh B, Ronghe AM, Chatterjee A, Bhat NK
and Bhat HK: MicroRNA-93 regulates NRF2 expression and is
associated with breast carcinogenesis. Carcinogenesis.
34:1165–1172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Qi Y, Xu L, Tao X, Han X, Yin L
and Peng J: MicroRNA-140-5p aggravates doxorubicin-induced
cardiotoxicity by promoting myocardial oxidative stress via
targeting Nrf2 and Sirt2. Redox Biol. 15:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Periti P and Mini E: Drug resistance in
cancer: An overview of the clinical aspects. J Chemother. 1:5–9.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y,
Wang Y, Chen Q, Zhao X, Zhou M, et al: MiR-181a enhances drug
sensitivity in mitoxantone-resistant breast cancer cells by
targeting breast cancer resistance protein (BCRP/ABCG2). Breast
Cancer Res Treat. 139:717–730. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai
XF, Yu ZJ, Wu HZ, Sun ML, Song ZG and Wei MJ: miR-487a resensitizes
mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by
targeting breast cancer resistance protein (BCRP/ABCG2). Cancer
Lett. 339:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwabedissen Meyer zu HE and Kroemer HK:
In vitro and in vivo evidence for the importance of breast cancer
resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp
Pharmacol. 1–371. 2011.
|
|
25
|
Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y,
Zhang Z, Su Y and Wang C: MicroRNA-130b targets PTEN to induce
resistance to cisplatin in lung cancer cells by activating
Wnt/β-catenin pathway. Cell Biochem Funct. 36:194–202. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niture SK and Jaiswal AK: Nrf2-induced
antiapoptotic Bcl-xL protein enhances cell survival and drug
resistance. Free Radic Biol Med. 57:119–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niture SK and Jaiswal AK: Nrf2 protein
up-regulates antiapoptotic protein Bcl-2 and prevents cellular
apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young LC, Campling BG, Cole SP, Deeley RG
and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2
in lung cancer: Correlation of protein levels with drug response
and messenger RNA levels. Clin Cancer Res. 7:1798–1804.
2001.PubMed/NCBI
|
|
29
|
Hayes JD, McMahon M, Chowdhry S and
Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated
through the Keap1-Nrf2 pathway. Antioxid Redox Signal.
13:1713–1748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Solis LM, Behrens C, Dong W, Suraokar M,
Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN,
et al: Nrf2 and Keap1 abnormalities in non-small cell lung
carcinoma and association with clinicopathologic features. Clin
Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Homma S, Ishii Y, Morishima Y, Yamadori T,
Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N,
et al: Nrf2 enhances cell proliferation and resistance to
anticancer drugs in human lung cancer. Clin Cancer Res.
15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
